Immunotherapeutic control of MHC I-heterogeneous tumors to minimize therapy resistance 2307892
The Journal of Immunology · 01.08.2026 · 215 (Supplement_1)
DOI: 10.1093/jimmun/vkag141.1402 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 28.07.2026. Verfasst von Abigail Mende und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
The anti-tumor activity of CD8 T cells, which recognize MHC I-presented tumor antigens, is enhanced by blocking checkpoint receptors. Longitudinal tumor biopsies from patients with acquired resistance to anti-PD-1 therapy often reveal genetic deficiencies in antigen presentation or MHC I expression. The role of CD8 T cells in selecting for MHC I-deficiency has been inferred but never demonstrated. Defining causes of MHC I loss and approaches to prevent it are essential for improving the outcomes of cancer immunotherapy.
Methods
To define immune cells responsible for selecting for outgrowth of MHC I-deficient tumors, we developed MHC I-mixed tumor models, applied immunotherapies, and depleted immune subsets. Tumor growth and composition (MHC I+ vs MHC I-) were determined.
Results
PD-1 blockade immunotherapy was poorly effective in mixed MHC I+/MHC I- tumor models and exerted potent selection mediated by CD8+ T cells for outgrowth of MHC I- cells. In contrast, IL-2 “superkines”, alone or in combination with STING agonists, were more effective and prevented outgrowth of MHC I- tumor cells in a manner dependent on multiple immune cell types. An alternative therapeutic approach in which Treg cells are depleted intratumorally also suppressed growth of both MHC I+ and MHC I- tumor cells, in this case largely independently of CD8 T cells.
Conclusion
We demonstrated for the first time in a controlled setting with mixed MHC I+/- tumors that anti-PD-1 therapy selects for outgrowth of MHC I-deficient tumor cells, dependent on CD8 T cells. Outgrowth of MHC I-deficient cells was minimized and mixed tumors were better controlled with IL-2 “superkine” therapy, alone or in combination with a STING agonist, and intratumoral Treg depletion. Tumor control in those cases was mediated by multiple effector cell types. Thus, immunotherapies that drive mixed responses of CD8+ and CD4+ T cells and NK cells have the potential to minimize acquired resistance resulting from MHC I loss. Funding Source NIH: R01CA270790 Topic Categories Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
Zitieren
APA
Mende, A., Cho, S., Zhang, C., DuPage, M., & Raulet, D. (2026). Immunotherapeutic control of MHC I-heterogeneous tumors to minimize therapy resistance 2307892. The Journal of Immunology, 215(Supplement_1). https://doi.org/10.1093/jimmun/vkag141.1402
Vancouver
Mende A, Cho S, Zhang C, DuPage M, Raulet D. Immunotherapeutic control of MHC I-heterogeneous tumors to minimize therapy resistance 2307892. The Journal of Immunology. 2026;215(Supplement_1). doi:10.1093/jimmun/vkag141.1402
BibTeX
@article{Mende2026,
author = {Mende, Abigail and Cho, Sooyun and Zhang, Chenyu and DuPage, Michel and Raulet, David},
title = {Immunotherapeutic control of MHC I-heterogeneous tumors to minimize therapy resistance 2307892},
journal = {The Journal of Immunology},
year = {2026},
volume = {215},
number = {Supplement_1},
doi = {10.1093/jimmun/vkag141.1402}
}
EUVIMED